Zimbabwe has rejected a significant US health deal worth $367m (£272m) over five years because of the United States' demand for confidential data.
The decision came to light after a internal memorandum from December was disclosed, indicating that Head of State Emmerson Mnangagwa believed the arrangement was "unbalanced".
An official spokesperson later stated that the US was seeking genetic material for research and commercial gain but was unwilling to guarantee the resulting advantages from future medical innovations.
"We must now begin the difficult and regrettable task of scaling back our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had donated more than $1.9bn in health funding to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged continued dialogue to secure a deal acceptable to all parties so the nation's vital HIV programme can continue.
Broader Implications
This rejection follows a similar case in neighbouring Kenya, where a court blocked a related deal with the US after legal challenges were raised about the safety of citizens' health data.
After returning to the presidency recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had administered aid for the US government, but Trump claimed its expenditure was "wasteful" and his government was seeking government-to-government deals to enhance transparency and accountability.
Based on reports, Sixteen nations in Africa have so far agreed to these new health pacts, representing over $18.3bn in new funding.
Details of the Declined Deal
This assistance for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this partnership would have delivered immense benefits for the people of Zimbabwe, particularly the 1.2 million currently receiving antiretroviral therapy via US-supported initiatives," Tremont said.
However, government spokesperson Nick Mangwana maintained the arrangement was "asymmetrical".
"The proposal required Zimbabwe to share its genetic material and health information for a long time, with no corresponding assurance of access to any scientific breakthroughs – like new medicines or tests – that could be developed from that shared data," his statement read.
"Effectively, our nation would provide the raw materials for scientific discovery with no certainty that the end products would be available to our citizens if a future pandemic emerge."
National Interest and Global Health
Mangwana further noted that the US's withdrawal from the global health body and its pursuit of bilateral deals were undermining frameworks previously established through the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework created to deal with future global health emergencies.
"This system is intended to ensure that when a nation contributes its information, the benefits – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome further discussions with our US partners on how subsequent collaboration might be arranged in a way that respects the independence and dignity of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the official position, but recommended that talks should continue given that much of the nation's Aids initiatives relied on foreign aid.
"In cases where specific concerns exist, including those relating to data governance or agreement terms, these can frequently be resolved through technical clarification and mutually agreed protections," the group added.
The situation emphasises the ongoing tensions between receiving vital foreign assistance and protecting local interests in an increasingly data-driven world.